EUVIMEDEUVIMED entdecken
Crossref

AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy

Emanuela Pannia iD, Rebecca Simonian, Nesrin Sabha, Nika Maani, Yingxuan Zhu, Sophie Karolczak iD, Vanessa Raileanu, Teodoro Bottiglieri iD, Gaia Andreoletti iD, Rachel D Edgar iD, Sonya A MacParland iD, Aleksandra Mitina iD und 6 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.adr1483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Emanuela Pannia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, University of Toronto, Toronto, Ontario, M5S 1A8, Canada. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Cholestasis, Myopathies, Structural, Congenital. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adeno-associated virus (AAV)–mediated liver injury is the primary off-target toxicity observed with viral gene therapy. Understanding of the underlying mechanisms has been hindered by the fact that murine studies poorly model AAV toxicity. The X-linked myotubular myopathy (XLMTM) gene therapy program epitomizes this therapeutic discordance, because a subset of participants treated with AAV8-driven myotubularin ( MTM1 ) gene replacement developed fatal liver injury that was not predicted by preclinical models. Here, we investigated a multihit hypothesis whereby loss of Mtm1 interacts with the postweaning environment to precipitate liver injury in XLMTM mouse models. Mtm1 knockout (KO) mice fed purified ingredient diets manifested liver dysfunction that mirrored patient clinical presentations, including elevated plasma transaminases, altered bile acid composition, and histological features of cholestasis. We further demonstrated a role for MTM1 in maintaining hepatocyte structure and localization of the bile salt export pump. Liver-specific deletion of Mtm1 recapitulated many of these features, supporting a liver-autonomous role for Mtm1 . Treatment of diet-sensitized mice with AAV8-driven gene therapy increased the susceptibility of cholestasis in global KO mice and induced liver injury in wild-type mice. Last, as a proof of concept, we treated global KO mice with lipid nanoparticle MTM1 gene replacement, which prevented development of key histopathological liver abnormalities. These findings provide critical insights into the environmental precipitants and molecular mechanisms of liver dysfunction in XLMTM and the adverse events seen in viral gene therapy studies and more broadly offer a framework to model AAV-associated toxicity and identify potential therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyCholestasisMyopathies, Structural, CongenitalDietAnimalsDisease Models, AnimalMice, KnockoutProtein Tyrosine Phosphatases, Non-ReceptorLiverBile Acids and SaltsMiceHepatocytesGene Therapy AgentsMaleMice, Inbred C57BL

Substanzen

Protein Tyrosine Phosphatases, Non-ReceptormyotubularinBile Acids and Salts

Autor:innen und Institutionen

  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.
  • Genetics and Genome Biology, SickKids Research Institute, Toronto, Ontario, M5G 0A4, Canada.
  • Center of Metabolomics, Institute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, TX 75204, USA.
  • Astellas Gene Therapies, San Francisco, CA 94108, USA.
  • Ajmera Transplant Centre, Toronto General Research Institute, University Health Network, Toronto, Ontario, M5G 2N2, Canada.
  • Donnelly Centre, University of Toronto, Toronto, Ontario, M5S 3E1, Canada.

ORCID-Profile: Emanuela Pannia, Sophie Karolczak, Teodoro Bottiglieri, Gaia Andreoletti, Rachel D Edgar, Sonya A MacParland, Aleksandra Mitina, Clara E Cho, Michael W Lawlor, Kirsten E Coleman, Barry J Byrne, Ashish R Deshwar, James J Dowling

Förderung

  • Canadian Institutes of Health Research
  • Astellas Pharma

Zitieren

APA

Pannia, E., Simonian, R., Sabha, N., Maani, N., Zhu, Y., Karolczak, S., Raileanu, V., Bottiglieri, T., Andreoletti, G., Edgar, R. D., MacParland, S. A., Mitina, A., Cho, C. E., Lawlor, M. W., Coleman, K. E., Byrne, B. J., Deshwar, A. R., & Dowling, J. J. (2026). AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adr1483

Vancouver

Pannia E, Simonian R, Sabha N, Maani N, Zhu Y, Karolczak S, et al. AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.adr1483

BibTeX
@article{Pannia2026,
  author = {Pannia, Emanuela and Simonian, Rebecca and Sabha, Nesrin and Maani, Nika and Zhu, Yingxuan and Karolczak, Sophie and Raileanu, Vanessa and Bottiglieri, Teodoro and Andreoletti, Gaia and Edgar, Rachel D and MacParland, Sonya A and Mitina, Aleksandra and Cho, Clara E and Lawlor, Michael W and Coleman, Kirsten E and Byrne, Barry J and Deshwar, Ashish R and Dowling, James J},
  title = {AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.adr1483}
}
Kostenlos starten →